Results 251 to 260 of about 701,274 (266)

Bias in progression‐free survival analysis due to intermittent assessment of progression

Statistics in Medicine, 2015
Richard Cook, Leilei Zeng, Lan Wen
exaly  

Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia: A Literature-Based Analysis

Current Oncology, 2015
Catherine Beauchemin, J B Johnston
exaly  

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Annals of Oncology, 2016
Stefan Michiels, S Paluch-Shimon, J Barinoff   +2 more
exaly  

Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival

Gynecologic Oncology, 2015
J Tate Thigpen
exaly  

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma

European Journal of Cancer, 2014
Robert Motzer, R A Figlin, B Korytowsky   +2 more
exaly  

A Review of Statistical Issues with Progression-Free Survival as an Interval-Censored Time-to-Event Endpoint

Journal of Biopharmaceutical Statistics, 2013
Xiaoyun Li
exaly  

Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice

European Journal of Cancer, 2014

exaly  

1H MRSI and progression-free survival in patients with WHO grades II and III gliomas

Neurological Research, 2010
Heinrich Lanfermann, Elke Hattingen
exaly  

Progression Free Survival and Overall Survival in NADIM II Study

2022
Provencio, M, Serna, R, Nadal, E, Larriba, JLG, Martinez-Marti, A, Bernabe, R, Bosch-Barrera, J, Benito, CG, Calvo, V, Insa, A, Ponce, S, Reguart, N, De Castro, J, Massuti, B, Palmero, R, de la Rosa, CA, Mosquera, J, Cobo, M, Aguilar, A, Vivanco, GL, Camps, C, Trancho, FH, Castro, RL, Moran, T, Barneto, I, Rodriguez-Abreu, D, Romero, A   +26 more
openaire   +1 more source

Osimertinib improves progression-free survival in NSCLC

The Lancet Oncology, 2018
openaire   +1 more source